Cornell University

University of Florida Research Foundation Inc

University of Southern California

The University of North Carolina at Chapel Hill

Memorial Sloan Kettering Cancer Center

University of Health Sciences & Pharmacy in St. Louis

Rajendra Uprety

Anthony A Sauve

Gareth R Tibbs

James David Warren, Jr

Peter A Goldstein

Rebecca L Joyce

Dipti N Barman

Gavril W Pasternak

Bryan Leo Roth

Jay McLaughlin

Susruta Majumdar

Saheem Zaidi

Vsevolod Katritch

Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HCN-related disorders (e.g., pain) with the compounds in a subject, by administering the compounds and/or compositions described herein.

Substituted alkylphenols as HCN1 antagonists

In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.

G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment

Growing community of inventors

Cary, NC, United States of America

Rajendra Uprety